HER-2: Combination Therapy of a HER2-DC1 Dendritic Cell Cancer Vaccine and a Probiotic

FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Haskell.Adler@Moffitt.org
(813) 745-6596

20MA016N